Ancestry.com takes DNA ownership rights from customers and their relatives
By Joel Winston,
Medium
| 05. 17. 2017
A word to the wise: Read the complete terms of service.
Don’t use the AncestryDNA testing service without actually reading the Ancestry.com Terms of Service and Privacy Policy. According to these legal contracts, you still own your DNA, but so does Ancestry.com.
The family history website Ancestry.com is selling a new DNA testing service called AncestryDNA. But the DNA and genetic data that Ancestry.com collects may be used against “you or a genetic relative.” According to its privacy policies, Ancestry.com takes ownership of your DNA forever. Your ownership of your DNA, on the other hand, is limited in years.
It seems obvious that customers agree to this arrangement, since all of them must “click here to agree” to these terms. But, how many people really read those contacts before clicking to agree? And how many relatives of Ancestry.com customers are also reading?
There are three significant provisions in the AncestryDNA Privacy Policy and Terms of Service to consider on behalf of yourself and your genetic relatives: (1) the perpetual, royalty-free, world-wide license to use your DNA; (2) the warning that DNA...
Related Articles
By Cade Metz and Karen Weise, The New York Times | 05.05.2025
Last month, an A.I. bot that handles tech support for Cursor, an up-and-coming tool for computer programmers, alerted several customers about a change in company policy. It said they were no longer allowed to use Cursor on more than...
By Anumita Kaur [cites CGS’ Katie Hasson], The Washington Post | 03.25.2025
Genetic information company 23andMe has said that it is headed to bankruptcy court, raising questions for what happens to the DNA shared by millions of people with the company via saliva test kits.
Sunday’s announcement clears the way for a new...
By Anna Louie Sussman, The New York Times | 03.25.2025
On June 24, 2022, the same day the Supreme Court issued its decision in Dobbs v. Jackson Women’s Health Organization, I received a call from the fertility clinic where I’d been undergoing in vitro fertilization, informing me that seven of...
By Michael Gibney, PharmaVoice | 03.20.2025
The death this week of a teenager receiving Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy is a tragic reminder of the stakes involved in cutting-edge biotech innovation.
While gene therapies like Sarepta’s offer an opportunity to treat and...
